WO2025083594 - PTPN2/PTP1B DEGRADER AND THERAPEUTIC METHOD THEREOF
National phase entry:
Publication Number
WO/2025/083594
Publication Date
24.04.2025
International Application No.
PCT/IB2024/060180
International Filing Date
17.10.2024
Title **
[English]
PTPN2/PTP1B DEGRADER AND THERAPEUTIC METHOD THEREOF
[French]
AGENT DE DÉGRADATION DE PTPN2/PTP1B ET SON PROCÉDÉ THÉRAPEUTIQUE
Applicants **
NORTHRIDGE HEALTH GROUP (HONG KONG) CO., LIMITED
Inventors
HAN, Lei
WU, Jinzi Jason
Priority Data
202311350130.3
18.10.2023
CN
63/544,959
20.10.2023
US
202410517098.1
26.04.2024
CN
202410935322.9
12.07.2024
CN
202411424577.5
12.10.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4048 | |
| EPO | Filing, Examination, Granting | 22346 | |
| Japan | Filing, Examination, Granting | 2740 | |
| South Korea | Filing, Examination, Granting | 3277 | |
| USA | Filing, Examination, Granting | 9890 |
Total:
42,301
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure describes a PTPN2/PTP1B degrader compounds having the structure of Formula (I), that are useful for treating PTPN2/ PTP1B-mediated disorders or conditions.[French]
La présente divulgation concerne des composés agents de dégradation de PTPN2/PTP1B ayant la structure de formule (I), qui sont utiles pour traiter des troubles ou des états médiés par PTPN2/PTP1B, formule (I).